Market Overview

ISIS Pharma Shares Jump Higher As Piper Jaffray Sees Co.'s Pipeline As 'Most Attractive and Undervalued' In Sector

Share:
Related ISIS
Piper Jaffray Makes 15 'Provocative' Predictions For Biopharma Sector In 2016
Benzinga's Top Initiations

Piper Jaffray analyst Joshua Schimmer sent ISIS Pharmaceuticals (NASDAQ: ISIS) shares six percent higher Friday morning with some bullish comments on the company.

In the report, Schimmer said he believes ISIS has the “most attractive and undervalued pipeline in biotech.” The analyst argued the undervaluation could be resolved with M&A activity or new management outlook.

Schimmer maintains an Overweight rating and $42 price target on shares of ISIS.

ISIS shares last traded at $26.43.

Latest Ratings for ISIS

DateFirmActionFromTo
Dec 2015Wells FargoInitiates Coverage onOutperform
Nov 2015Goldman SachsInitiates Coverage onNeutral
Nov 2015BarclaysMaintainsEqual-Weight

View More Analyst Ratings for ISIS
View the Latest Analyst Ratings

Posted-In: Analyst Color News Analyst Ratings

 

Related Articles (ISIS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MDRXKeyBancUpgrades0.0
ANETNomuraUpgrades260.0
CNPRBC CapitalUpgrades34.0
FISVOppenheimerUpgrades88.0
FNDUBSUpgrades37.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: D.A. Davidson & Co. Reiterates On Zumiez On Encouraging 1Q Upside

Shares Of Aruba Networks Drop In The #PreMarket Despite Record Revenue